218 related articles for article (PubMed ID: 37222047)
1. Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy.
Ji P; Sun W; Zhang S; Xing Y; Wang C; Wei M; Li Q; Ji G; Yang G
Adv Sci (Weinh); 2023 Aug; 10(22):e2301789. PubMed ID: 37222047
[TBL] [Abstract][Full Text] [Related]
2. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
[TBL] [Abstract][Full Text] [Related]
3. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
5. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
6. An injectable thermosensitive hydrogel/nanomicelles composite for local chemo-immunotherapy in mouse model of melanoma.
Akbari V; Hejazi E; Minaiyan M; Emami J; Lavasanifar A; Rezazadeh M
J Biomater Appl; 2022 Sep; 37(3):551-562. PubMed ID: 35543695
[TBL] [Abstract][Full Text] [Related]
7. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
9. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
[TBL] [Abstract][Full Text] [Related]
10. Nano-hydroxyapatite-evoked immune response synchronized with controllable immune adjuvant release for strengthening melanoma-specific growth inhibition.
Chen Z; Deng J; Cao J; Wu H; Feng G; Zhang R; Ran B; Hu K; Cao H; Zhu X; Zhang X
Acta Biomater; 2022 Jun; 145():159-171. PubMed ID: 35398268
[TBL] [Abstract][Full Text] [Related]
11. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
12. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo stimulation of tumor-draining lymph node cells from lung cancer patients: a potential resource for adoptive immunotherapy.
Shan B; Li Q; He M; He Y
Cell Mol Immunol; 2008 Aug; 5(4):307-13. PubMed ID: 18761819
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
15. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
[TBL] [Abstract][Full Text] [Related]
16. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
[TBL] [Abstract][Full Text] [Related]
17. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.
Dessureault S; Alsarraj M; McCarthy S; Hunter T; Noyes D; Lee D; Harkins J; Seigne J; Jennings R; Antonia SJ
J Surg Res; 2005 May; 125(2):173-81. PubMed ID: 15854671
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in GM-CSF-based cancer immunotherapy.
Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
20. Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment.
Yan WL; Wu CC; Shen KY; Liu SJ
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
